v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses        
Research and development $ 6,528 $ 3,182 $ 15,720 $ 5,608
General and administrative 3,649 1,880 11,578 4,121
Total operating expenses 10,177 5,062 27,298 9,729
Operating loss (10,177) (5,062) (27,298) (9,729)
Other (expense) income:        
Interest expense - royalty agreement (1,510) (1,017) (4,079) (2,764)
Interest expense - convertible notes payable 0 (220) 0 (249)
Fair value adjustments on derivative liabilities - royalty agreement (82) (75) (275) (404)
Fair value adjustments on convertible notes payable 0 (568) 0 (568)
Fair value adjustments on derivative liabilities - contingent value right agreement (238) 0 (238) 0
Interest income (expense), net 628 187 2,070 361
Other income (expense), net 34 (20) 819 (130)
Loss before income taxes (11,345) (6,775) (29,001) (13,483)
Income tax benefit (expense) 0 0 0 0
Net loss (11,345) (6,775) (29,001) (13,483)
Less: Cumulative Series D preferred dividends 0 (194) 0 (582)
Loss attributable to common stockholders (11,345) (6,969) (29,001) (14,065)
Other comprehensive loss:        
Foreign currency translation gain 215 0 101 0
Comprehensive loss $ (11,130) $ (6,969) $ (28,900) $ (14,065)
Net loss per share of Common Stock - basic (in dollars per share) $ (1.03) $ (3.94) $ (2.63) $ (7.95)
Net loss per share of Common Stock - diluted (in dollars per share) $ (1.03) $ (3.94) $ (2.63) $ (7.95)
Weighted-average shares used in computing net loss per share of Common Stock - basic (in shares) 11,064,282 1,770,167 11,043,758 1,770,167
Weighted-average shares used in computing net loss per share of Common Stock - diluted (in shares) 11,064,282 1,770,167 11,043,758 1,770,167